NCT00711841

Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome

Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Instituto Materno Infantil Prof. Fernando Figueira · Academic / Other
• Sex: Female
• Age: 13 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of blood products and shorter hospital stay.

Detailed description

Patients with Class I HELLP Syndrome will be recruited for use os dexamethasone or placebo in the puerperium. Effects such as clinical course (blood pressure and diureses), laboratorial behaviour and complications will be compared. Duration of hospitalization will also be accessed.

Conditions

• HELLP Syndrome

Interventions

Type	Name	Description
DRUG	dexamethasone	Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
DRUG	Placebo	Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
DRUG	dexamethasone	dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours

Timeline

• Start date: 2011-07-01
• Primary completion: 2019-06-01
• Completion: 2019-06-01
• First posted: 2008-07-09
• Last updated: 2019-06-06

Locations

1 site across 1 country: Brazil